Q-omics provides the consensus-scored MUC5B profile across patient tissues and cancer cell-line models. MUC5B expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, MUC5B is differentially expressed in 11, with the highest sampling consensus in LUAD. Additionally, MUC5B protein abundance shows 23,368 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, LUAD, and GBM as cancer lineages where MUC5B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MUC5B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MUC5B survival associations across molecular data types. MUC5B RNA expression shows survival associations in the most cancer types (26), followed by mutation status (10) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MUC5B RNA expression–survival associations across cancer types. High MUC5B expression shows unfavorable associations in KIRC, LUAD, ACC, MESO and THCA, but favorable associations in UCEC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for MUC5B RNA expression.
This table summarizes MUC5B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 5. The strongest signals are observed in LUAD for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for MUC5B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MUC5B shows lower tumor expression in HNSC and higher tumor expression in LUAD, PAAD, BRCA, ESCA and STAD. The LUAD box plot shows higher MUC5B RNA expression in tumor versus normal tissue (log2 FC = +3.199, t-test p < 0.001).
This table shows molecular features associated with MUC5B in patient tissues and cancer cell lines. In patient samples, MUC5B shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, MUC5B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in BREAST and LARGE_INTESTINE.
